Person:
ACET ÖZTÜRK, NİLÜFER AYLİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ACET ÖZTÜRK

First Name

NİLÜFER AYLİN

Name

Filters

2015 - 201942020 - 202317
Reset filters

Settings

Search Results

Now showing 1 - 10 of 21
  • No Thumbnail Available
    Publication
    Comorbid conditions and social determinants of smoking in an adult population
    (Turkish Green Crescent Soc, 2019-12-01) Güçlü, Özge Aydın; Öztürk, Nilufer Aylin Acet; GÖREK DİLEKTAŞLI, ASLI; ACET ÖZTÜRK, NİLÜFER AYLİN; DEMİRDÖĞEN, EZGİ; Demirdöğen, Ezgi; Uzaslan, Esra; UZASLAN, AYŞE ESRA; Karadağ, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0003-1005-3205; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-9027-1132; Z-1424-2019; AAG-8744-2021; JPK-7012-2023; AAH-9812-2021
    Tobacco smoking is a significant risk factor for a variety of chronic disorders, such as chronic obstructive pulmonary disease (COPD), lung cancer, cardiovascular diseases, and other forms of malignancies. In this study, we investigated the comorbid medical conditions and sociodemographic features that contribute to disparities in tobacco smoking prevalence in the adult population. We induded volunteers who participated in events for the "World COPD day" in 4 consecutive years (i.e., 2014, 2015, 2016, and 2017) held in Bursa, Turkey. Sociodemographic features, smoking characteristics, and comorbidities were recorded. A total of 747 volunteers who were 47.1 +/- 14.5 [16-84] years of age and smoked 24.1 +/- 20.91 pack-years were included. The study population consisted of 405 (54.2%) males, 36.3% of which were current smokers, 23.6% exsmokers, and 40.2% nonsmokers. Moreover, 15.7% of participants with asthma were nonsmokers and 9.4% ever-smoker (p=0.011), while 2% of participants with coronary artery disease (CAD) were nonsmoker and 6.7% were ever-smoker (p=0.003). Current smoker participants exhibited more symptoms such as cough. sputum, and wheezing (p<0.001, in both cases). In this study, we found that the factors associated with smoking in the general population are male gender and higher educational level.
  • Thumbnail Image
    Publication
    Response to "Hypercapnic respiratory failure with insufficient response to fixed- level PS-NIV: Is AVAPS the end solution?"
    (Turkish Assoc Tuberculosis & Thorax, 2023-01-01) Öztürk, Nilüfer Aylin Acet; Güçlü, Özge Aydın; Demirdoğen, Ezgi; Dilektaşlı, Aslı Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; Z-1424-2019; AAG-9930-2019; AAH-9812-2021; DTT-7416-2022; DDT-7334-2022; AAD-1271-2019; CDI-1977-2022; AAG-8744-2021
  • Thumbnail Image
    Publication
    Development and validation of a simple risk scoring system for a COVİD-19 diagnostic prediction model
    (Tüberküloz ve Toraks, 2023-01-01) Güçlü, Özge Aydın; Ursavaş, Ahmet; Ocakoğlu, Gokhan; Demirdogen, Ezgi; Öztürk, Nilufer Aylin Acet; Topçu, Dilara Ömer; Terzi, Orkun Eray; Onal, Uğur; Dilektaşlı, Aslı Görek; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; AkalIn, Halis; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; OCAKOĞLU, GÖKHAN; DEMİRDÖĞEN, EZGİ; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖMER TOPÇU, DİLARA; TERZİ, ORKUN ERAY; ÖNAL, UĞUR; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; AkalIn, Halis; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; 0000-0003-1005-3205; 0000-0002-1114-6051; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-2954-4293; 0000-0001-7530-1279; 0000-0002-9027-1132; AAH-5180-2021; A-4970-2019; AAG-8744-2021; AAI-3169-2021; JCO-3678-2023; JPK-7012-2023
    Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to find a predictive scoring model to estimate the COVID-19 diagnosis.Materials and Methods: Patients who applied to the emergency pandemic clinic between April 2020 and March 2021 were enrolled in this retrospective study. At admission, demographic characteristics, symptoms, comorbid diseases, chest computed tomography (CT), and laboratory findings were all recorded. Development and validation datasets were created. The scoring system was performed using the coefficients of the odds ratios obtained from the multivariable logistic regression analysis.Results: Among 1187 patients admitted to the hospital, the median age was 58 years old (22-96), and 52.7% were male. In a multivariable analysis, typical radiological findings (OR= 8.47, CI= 5.48-13.10, p< 0.001) and dyspnea (OR= 2.85, CI= 1.71-4.74, p< 0.001) were found to be the two important risk factors for COVID-19 diagnosis, followed by myalgia (OR= 1.80, CI= 1.082.99, p= 0.023), cough (OR= 1.65, CI= 1.16-2.26, p= 0.006) and fatigue symptoms (OR= 1.57, CI= 1.06-2.30, p= 0.023). In our scoring system, dyspnea was scored as 2 points, cough as 1 point, fatigue as 1 point, myalgia as 1 point, and typical radiological findings were scored as 5 points. This scoring system had a sensitivity of 71% and a specificity of 76.3% for a cut-off value of >2, with a total score of 10 (p< 0.001).Conclusion: The predictive scoring system could accurately predict the diagnosis of COVID-19 infection, which gave clinicians a theoretical basis for devising immediate treatment options. An evaluation of the predictive
  • Thumbnail Image
    Publication
    AVAPS-NIV treatment in hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV
    (Türk Tüberküloz ve Toraks, 2022-01-01) Öztürk, Nilüfer Aylın Acet; Güçlü, Özge Aydın; Demirdöğen, Ezgi; Dilektaşlı, Asli Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; DDT-7334-2022
    Introduction: Noninvasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF) is an established treatment modality. Current evidence does not conclude any superiority between fixed pressure support (PS) and aver-age volume-assured pressure support (AVAPS) modes. However, given the ability of rapid PaCO2 decline in AVAPS mode, we hypothesized that COPD patients with AHRF who did not show the desired reduction in PaCO2 with fixed-level PS-NIV might benefit from the AVAPS mode.Materials and Methods: Patients admitted to the non-ICU pulmonary ward with acute exacerbation of COPD (AECOPD) and AHRF were included con-secutively in this observational study. Patients with hypercapnic respiratory failure due to obesity-hypoventilation, neurological diseases, or chest wall deformities were excluded. All patients started NIV treatment with fixed pres-sure support (PS) and patients who did not reach clinical and laboratory stability under PS-NIV treatment were switched to the average volume -as-sured pressure support (AVAPS) mode of NIV.Results: Thirty-five COPD patients with hypercapnic respiratory failure were included. Under PS-NIV treatment, 14 (40%) patients showed a 17.9 (-0.0-29.2) percent change in terms of PaCO2 , meaning no improvement or worsening. Therefore, these patients were treated with AVAPS mode. Arterial PaCO2 and pH levels significantly improved after AVAPS-NIV administration. AVAPS-NIV treatment created a significantly better PaCO2 change rate than using PS-NIV (-11.4 (-22.0 --0.5)vs 8.2 (-5.3-19.5), p= 0.02]. Independent predictors of AVAPS mode requirement were higher Charlson Comorbidity Index (OR= 1.74 (95% CI= 1.02-2.97)] and higher PaCO2 upon admission (OR= 1.18 (95% CI= 1.03-1.35)]. Thirteen (92.8%) patients reaching signif-icant clinical stability with AVAPS-NIV were able to return to fixed-level PS-NIV and maintain acceptable PaCO2 levels.Conclusion: Our study demonstrated that patients can benefit from AVAPS-NIV despite insufficient response to fixed-level PS-NIV.
  • No Thumbnail Available
    Publication
    Frailty: An indicator for poor outcomes among in-hospital pulmonology patients
    (European Respiratory Soc Journals, 2021-09-05) Öztürk, Nilüfer Aylin Acet; Dilektaşlı, Aslı Görek; Güçlü, Özge Aydın; Ursavaş, Ahmet; Demirdoğen, Ezgi; Coşkun, Funda; Uzaslan, Esra; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; JPK-7012-2023; AAG-8744-2021; AAD-1271-2019; Z-1424-2019; CNP-1063-2022; AAG-9930-2019; CDI-1977-2022
  • Thumbnail Image
    Publication
    A fatal complication of dermatomyositis: Spontaneous pneumomediastinum
    (Kare Yayınevi, 2016-04-01) Çetinoğlu, Ezgi Demirdoğen; Dalkılıç, Ediz; Erol, Muharrem; Acet, Nilüfer Aylin; Ursavaş, Ahmet; Ege, Ercüment; Çetinoğlu, Ezgi Demirdoğen; DALKILIÇ, HÜSEYİN EDİZ; Erol, Muharrem; ACET ÖZTÜRK, NİLÜFER AYLİN; URSAVAŞ, AHMET; Ege, Ercüment; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Romatoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; 0000-0002-7400-9089; 0000-0002-6375-1472; AAH-9812-2021; JHC-5173-2023; JEN-3243-2023; Z-1424-2019; AAI-3169-2021; CPF-5844-2022
    Interstitial lung disease (ILD) is a negative prognostic factor associated with increased morbidity and mortality in patients with dermatomyositis (DM). Spontaneous pneumomediastinum is a rare complication of DM and it can be fatal. We present a 48-year-old woman with DM and ILD complicated by pneumomediastinum without pneumothorax and subcutaneous emphysema.
  • No Thumbnail Available
    Publication
    Association of fatigue with mental well-being, quality of life and exercise capacity in sarcoidosis: A case-control comparision
    (Amer, 2015-01-01) Dilektaşlı, Aslı Görek; Çetinoğlu, E. Demirdöğen; Acet, N. Aylin; Gökmen, Nilüfer E.; Karadağ, Mehmet; Uzaslan, Esra; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, E. Demirdöğen; ACET ÖZTÜRK, NİLÜFER AYLİN; KARADAĞ, MEHMET; UZASLAN, AYŞE ESRA; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0002-9027-1132; Z-1424-2019; JPK-7012-2023; AAG-8744-2021; DTT-7416-2022; AAH-9812-2021; Z-1424-2019; CQV-5946-2022; CDI-1977-2022
  • No Thumbnail Available
    Publication
    Respiratory morbidity and exacerbations in patients with copd diagnosed with the fixed ratio and the lower limit of normal
    (European Respiratory Soc Journals Ltd, 2023-09-09) Dilektaşlı, Aslı Görek; GÖREK DİLEKTAŞLI, ASLI; COŞKUN, NECMİYE FUNDA; Yiğitliler, Büşra; Öztürk, Nilufer; ACET ÖZTÜRK, NİLÜFER AYLİN; UZASLAN, AYŞE ESRA; Uzaslan, Esra; Karadağ, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0001-7099-9647; 0000-0002-9027-1132; AAG-8744-2021
  • Thumbnail Image
    Publication
    Serum cancer from lung-6: Promising biomarker to differentiate cpfe from ipf
    (Mattioli 1885, 2022-01-01) Uzaslan, Esra; DEMİRDÖĞEN, EZGİ; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; ÖZKAYA, GÜVEN; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer Aylin Acet; Karadağ, Mehmet; KARADAĞ, MEHMET; ACET ÖZTÜRK, NİLÜFER AYLİN; YEŞİLBURSA, DİLEK; Yeşilbursa, Dilek; Budak, Ferah; BUDAK, FERAH; Öztürk, Alper; Ursavaş, Ahmet; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı.; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-6375-1472; 0000-0001-7625-9148; 0000-0003-3604-8826; 0000-0003-0297-846X; 0000-0002-9027-1132; AAD-1271-2019; JPK-7012-2023; IZP-9398-2023; A-4421-2016; F-4657-2014; AAI-3169-2021; AAG-8744-2021
    Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.
  • Thumbnail Image
    Publication
    Pilot study for immunoglobulin E as a prognostic biomarker in coronavirus disease 2019
    (Wiley, 2022-08-19) Güçlü, Özge Aydın; Göktaş, Seda S.; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer A. Acet; Demirdoğen, Ezgi; Coşkun, Funda; Ediger, Dane; Ursavaş, Ahmet; Uzaslan, Esra; Erol, Haşim A.; Karacay, Nurdan D.; Sel, Umut Kaya; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; GÖREK DİLEKTAŞLI, ASLI; ACET ÖZTÜRK, NİLÜFER AYLİN; DEMİRDÖĞEN, EZGİ; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; URSAVAŞ, AHMET; UZASLAN, AYŞE ESRA; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı/İmmünoloji ve Alerji Hastalıkları Bilim Dalı.; 0000-0003-3604-8826 ; 0000-0002-9027-1132 ; 0000-0002-7400-9089 ; 0000-0002-6375-1472 ; 0000-0003-1005-3205 ; AAG-9930-2019; DTT-7416-2022; Z-1424-2019; AAH-9812-2021; AAD-1271-2019; AAE-9142-2019; AAI-3169-2021; CDI-1977-2022; AAG-8744-2021
    Background Laboratory biomarkers to estimate the severity of coronavirus disease 2019 (COVID-19) are crucial during the pandemic since resource allocation must be carefully planned. Aims To evaluate the effects of basal serum total immunoglobulin E (IgE) levels and changes in inflammatory parameters on the clinical progression of patients hospitalised with COVID-19. Methods Patients hospitalised with confirmed COVID-19 were included in the study. Laboratory data and total IgE levels were measured on admission. Lymphocyte, eosinophil, ferritin, d-dimer and C-reactive protein parameters were recorded at baseline and on the 3rd and 14th days of hospitalisation. Results The study enrolled 202 patients, of which 102 (50.5%) were males. The average age was 50.17 +/- 19.68 years. Of the COVID-19 patients, 41 (20.3%) showed clinical progression. Serum total IgE concentrations were markedly higher (172.90 (0-2124) vs 38.70 (0-912); P < 0.001) and serum eosinophil levels were significantly lower (0.015 (0-1.200) vs 0.040 (0-1.360); P = 0.002) in clinically worsened COVID-19 patients when compared with stable patients. The optimal cut-off for predicting clinical worsening was 105.2 ng/L, with 61% sensitivity, 82% specificity, 46.3% positive predictive value and 89.2% negative predictive value (area under the curve = 0.729). Multivariable analysis to define risk factors for disease progression identified higher total IgE and C-reactive protein levels as independent predictors. Conclusions Our single-centre pilot study determined that total IgE levels may be a negative prognostic factor for clinical progression in patients hospitalised due to COVID-19 infection. Future studies are required to determine the impact of individuals' underlying immune predispositions on outcomes of COVID-19 infections.